Indianapolis-based pharmaceutical giant Eli Lilly and Company has purchased 30.9 acres of vacant land to the north and to the ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE ... to create an advanced manufacturing and drug development center at its Indiana facility, which comes on the heels ...

To learn more about how we handle and protect your data, visit our privacy center. Maintaining independence and editorial freedom is essential to our mission of empowering investor success.

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by ...

Shares of Eli Lilly and Co. slumped toward their biggest ... Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter ...

SALISBURY — Rowan-Cabarrus Community College and its students recently benefited from involvement with Eli Lilly and Company and its annual Global Day of Service. Student participation is key to ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...